#Bioretec #Finland #Tampere #RemeOs #Tuukka Paavola

Bioretec Ltd's Managerial Update

Bioretec Oy, a pioneering Finnish company specialized in medical devices, announced noteworthy transactions conducted by its Chief Financial Officer, Tuukka Paavola. This release, dated April 27, 2026, outlines the key details surrounding these managerial transactions.

Overview of Transactions

On April 24, 2026, Tuukka Paavola participated in a substantial share subscription for Bioretec Oy, a strategic move suggesting confidence in the company’s future and market position. Under the transaction, Paavola subscribed to 2,000,000 shares at a price of 0.01 EUR each, primarily through the First North Growth Market in Finland.

Transaction Details

• - Name: Tuukka Paavola
• - Position: Chief Financial Officer
• - Issuer: Bioretec Oy
• - Transaction Date: April 24, 2026
• - Venue: First North Growth Market Finland (FSME)
• - Type of Instrument: Share
• - Volume: 2,000,000 shares
• - Unit Price: 0.01 EUR
• - Aggregated Transaction Value: 20,000 EUR

This strategic investment by Paavola signifies a strong alignment with the company’s strategic goals, particularly as Bioretec continues to innovate in the medical field.

About Bioretec Oy

Bioretec is renowned globally for its revolutionary medical device solutions, primarily in orthopedics. The company specializes in developing biodegradable implants that support bone growth and facilitate healing post-surgery. These innovations are not just limited to Finland; Bioretec's products are utilized in approximately 40 countries worldwide.

Innovative Product Lines

Among its latest product offerings, Bioretec has successfully launched the RemeOs™ line, consisting of a high-performance magnesium alloy and hybrid composites. These implants are notable for their absorptive qualities, which allow them to be replaced by natural bone over time, thus eliminating the need for surgical removal after healing.

The first product in this line received market authorization in the U.S. in March 2023 and gained CE mark approval in Europe in January 2025. The company's Activa product range also boasts fully bioabsorbable orthopedic implants, utilizing a proprietary PLGA formulation approved by both CE and FDA for various pediatric and adult medical applications.

Future Implications

The recent transaction not only reflects confidence from Bioretec’s leadership but is also poised to bolster investor trust in the company’s growth trajectory. As Bioretec continues to advance its innovative solutions in orthopedic care, the focus remains on enhancing outcomes for patients while maintaining sustainable business practices.

With a commitment to transforming healthcare through technology and biocompatibility, Bioretec Oy is expected to play a crucial role in the future of orthopedic treatments, carving out a niche centered on healing through absorption.

For more information about Bioretec and their groundbreaking technologies, visit www.bioretec.com.